CHANGMAO BIO (00954) Income Statement & Earnings

0.340
+0.010+3.03%

Not Open May 13 15:48 CST

180.10MMarket Cap-2.43P/E (TTM)

CHANGMAO BIO (00954) Income Statement

All

YOY

Hide blank lines

(FY)Dec 31, 2025

(Q6)Jun 30, 2025

(FY)Dec 31, 2024

(Q6)Jun 30, 2024

(FY)Dec 31, 2023

(Q6)Jun 30, 2023

(FY)Dec 31, 2022

(Q6)Jun 30, 2022

(FY)Dec 31, 2021

(Q6)Jun 30, 2021

Turnover

-4.77%556.93M

-13.23%272.28M

-8.21%584.79M

5.80%313.8M

-12.73%637.08M

-22.52%296.61M

33.22%730.03M

55.39%382.81M

23.39%547.98M

12.01%246.36M

Operating income

-4.77%556.93M

-13.23%272.28M

-8.21%584.79M

5.80%313.8M

-12.73%637.08M

-22.52%296.61M

33.22%730.03M

55.39%382.81M

23.39%547.98M

12.01%246.36M

Cost of sales

5.09%-539.09M

12.99%-259.13M

7.08%-568.02M

-16.73%-297.82M

-11.30%-611.27M

12.56%-255.14M

-7.84%-549.2M

-34.72%-291.8M

-46.07%-509.3M

-27.43%-216.6M

Operating expenses

5.09%-539.09M

12.99%-259.13M

7.08%-568.02M

-16.73%-297.82M

-11.30%-611.27M

12.56%-255.14M

-7.84%-549.2M

-34.72%-291.8M

-46.07%-509.3M

-27.43%-216.6M

Gross profit

6.29%17.83M

-17.74%13.15M

-35.00%16.78M

-61.45%15.99M

-85.73%25.81M

-54.44%41.47M

367.51%180.83M

205.88%91.02M

-59.48%38.68M

-40.46%29.76M

Selling expenses

1.17%-10.06M

-4.82%-4.4M

-17.09%-10.17M

-16.69%-4.19M

-3.18%-8.69M

-11.55%-3.59M

-2.57%-8.42M

5.98%-3.22M

-29.50%-8.21M

44.48%-3.43M

Administrative expenses

7.43%-65.58M

5.04%-32.02M

5.06%-70.85M

-5.25%-33.72M

15.73%-74.62M

22.35%-32.03M

-20.49%-88.55M

-40.83%-41.26M

-3.66%-73.49M

-18.65%-29.3M

Impairment and provision

120.00%41K

----

-12.02%-205K

----

-234.56%-183K

----

585.71%136K

-98.91%2K

-123.33%-28K

88.66%183K

-Other impairment is provision

120.00%41K

----

-12.02%-205K

----

-234.56%-183K

----

585.71%136K

-98.91%2K

-123.33%-28K

88.66%183K

Special items of operating profit

27.24%9.39M

-48.61%3.78M

31.00%7.38M

155.86%7.35M

4.86%5.63M

7.28%2.87M

-95.83%5.37M

41.17%2.68M

9,702.68%128.87M

54.98%1.9M

Operating profit

15.24%-48.37M

-33.72%-19.49M

-9.64%-57.07M

-267.21%-14.57M

-158.24%-52.05M

-82.29%8.72M

4.14%89.37M

5,642.34%49.22M

404.88%85.82M

-104.35%-888K

Financing income

-25.30%632K

-45.98%289K

-19.51%846K

8.30%535K

11.81%1.05M

-3.52%494K

75.05%940K

63.06%512K

149.77%537K

220.41%314K

Financing cost

-51.63%-17.23M

-77.47%-6.04M

-49.81%-11.36M

-6.04%-3.41M

-184.11%-7.58M

-103.74%-3.21M

-36.73%-2.67M

-180.43%-1.58M

-3,048.39%-1.95M

-1,378.95%-562K

Earning before tax

3.88%-64.96M

-44.70%-25.24M

-15.37%-67.58M

-390.80%-17.44M

-166.84%-58.58M

-87.54%6M

3.83%87.64M

4,338.73%48.15M

392.12%84.41M

-105.54%-1.14M

Tax

-229.90%-2.21M

34.04%-748K

97.61%-669K

45.53%-1.13M

-344.45%-27.94M

72.23%-2.08M

76.01%-6.29M

-748.06%-7.5M

-6,306.36%-26.2M

120.99%1.16M

After-tax profit from continuing operations

1.58%-67.17M

-39.90%-25.99M

21.11%-68.25M

-574.36%-18.58M

-206.34%-86.52M

-90.37%3.92M

39.77%81.36M

193,490.48%40.65M

247.65%58.21M

-99.86%21K

Earning after tax

1.58%-67.17M

-39.90%-25.99M

21.11%-68.25M

-574.36%-18.58M

-206.34%-86.52M

-90.37%3.92M

39.77%81.36M

193,490.48%40.65M

247.65%58.21M

-99.86%21K

Minority profit

-4,987.50%-407K

-193.81%-197K

98.26%-8K

187.14%210K

-609.23%-461K

-6.64%-241K

41.44%-65K

-2.26%-226K

-32.14%-111K

-9.41%-221K

Profit attributable to shareholders

2.17%-66.76M

-37.28%-25.79M

20.70%-68.24M

-551.91%-18.79M

-205.69%-86.06M

-89.83%4.16M

39.62%81.42M

16,792.56%40.88M

246.57%58.32M

-98.41%242K

Basic earnings per share

2.33%-0.126

-40.00%-0.049

20.37%-0.129

-537.50%-0.035

-205.19%-0.162

-89.61%0.008

40.00%0.154

0.077

243.75%0.11

Diluted earnings per share

2.33%-0.126

-40.00%-0.049

20.37%-0.129

-537.50%-0.035

-205.19%-0.162

-89.61%0.008

40.00%0.154

0.077

243.75%0.11

Currency Unit

CNY

Accounting Standards

HKAS

Audit Opinions

Unqualified Opinion

Auditor

PwC Zhongtian Certified Public Accountants (Special General Partnership)

	(FY)Dec 31, 2025	(Q6)Jun 30, 2025	(FY)Dec 31, 2024	(Q6)Jun 30, 2024	(FY)Dec 31, 2023	(Q6)Jun 30, 2023	(FY)Dec 31, 2022	(Q6)Jun 30, 2022	(FY)Dec 31, 2021	(Q6)Jun 30, 2021
Turnover	-4.77%556.93M	-13.23%272.28M	-8.21%584.79M	5.80%313.8M	-12.73%637.08M	-22.52%296.61M	33.22%730.03M	55.39%382.81M	23.39%547.98M	12.01%246.36M
Operating income	-4.77%556.93M	-13.23%272.28M	-8.21%584.79M	5.80%313.8M	-12.73%637.08M	-22.52%296.61M	33.22%730.03M	55.39%382.81M	23.39%547.98M	12.01%246.36M
Cost of sales	5.09%-539.09M	12.99%-259.13M	7.08%-568.02M	-16.73%-297.82M	-11.30%-611.27M	12.56%-255.14M	-7.84%-549.2M	-34.72%-291.8M	-46.07%-509.3M	-27.43%-216.6M
Operating expenses	5.09%-539.09M	12.99%-259.13M	7.08%-568.02M	-16.73%-297.82M	-11.30%-611.27M	12.56%-255.14M	-7.84%-549.2M	-34.72%-291.8M	-46.07%-509.3M	-27.43%-216.6M
Gross profit	6.29%17.83M	-17.74%13.15M	-35.00%16.78M	-61.45%15.99M	-85.73%25.81M	-54.44%41.47M	367.51%180.83M	205.88%91.02M	-59.48%38.68M	-40.46%29.76M
Selling expenses	1.17%-10.06M	-4.82%-4.4M	-17.09%-10.17M	-16.69%-4.19M	-3.18%-8.69M	-11.55%-3.59M	-2.57%-8.42M	5.98%-3.22M	-29.50%-8.21M	44.48%-3.43M
Administrative expenses	7.43%-65.58M	5.04%-32.02M	5.06%-70.85M	-5.25%-33.72M	15.73%-74.62M	22.35%-32.03M	-20.49%-88.55M	-40.83%-41.26M	-3.66%-73.49M	-18.65%-29.3M
Impairment and provision	120.00%41K	----	-12.02%-205K	----	-234.56%-183K	----	585.71%136K	-98.91%2K	-123.33%-28K	88.66%183K
-Other impairment is provision	120.00%41K	----	-12.02%-205K	----	-234.56%-183K	----	585.71%136K	-98.91%2K	-123.33%-28K	88.66%183K
Special items of operating profit	27.24%9.39M	-48.61%3.78M	31.00%7.38M	155.86%7.35M	4.86%5.63M	7.28%2.87M	-95.83%5.37M	41.17%2.68M	9,702.68%128.87M	54.98%1.9M
Operating profit	15.24%-48.37M	-33.72%-19.49M	-9.64%-57.07M	-267.21%-14.57M	-158.24%-52.05M	-82.29%8.72M	4.14%89.37M	5,642.34%49.22M	404.88%85.82M	-104.35%-888K
Financing income	-25.30%632K	-45.98%289K	-19.51%846K	8.30%535K	11.81%1.05M	-3.52%494K	75.05%940K	63.06%512K	149.77%537K	220.41%314K
Financing cost	-51.63%-17.23M	-77.47%-6.04M	-49.81%-11.36M	-6.04%-3.41M	-184.11%-7.58M	-103.74%-3.21M	-36.73%-2.67M	-180.43%-1.58M	-3,048.39%-1.95M	-1,378.95%-562K
Earning before tax	3.88%-64.96M	-44.70%-25.24M	-15.37%-67.58M	-390.80%-17.44M	-166.84%-58.58M	-87.54%6M	3.83%87.64M	4,338.73%48.15M	392.12%84.41M	-105.54%-1.14M
Tax	-229.90%-2.21M	34.04%-748K	97.61%-669K	45.53%-1.13M	-344.45%-27.94M	72.23%-2.08M	76.01%-6.29M	-748.06%-7.5M	-6,306.36%-26.2M	120.99%1.16M
After-tax profit from continuing operations	1.58%-67.17M	-39.90%-25.99M	21.11%-68.25M	-574.36%-18.58M	-206.34%-86.52M	-90.37%3.92M	39.77%81.36M	193,490.48%40.65M	247.65%58.21M	-99.86%21K
Earning after tax	1.58%-67.17M	-39.90%-25.99M	21.11%-68.25M	-574.36%-18.58M	-206.34%-86.52M	-90.37%3.92M	39.77%81.36M	193,490.48%40.65M	247.65%58.21M	-99.86%21K
Minority profit	-4,987.50%-407K	-193.81%-197K	98.26%-8K	187.14%210K	-609.23%-461K	-6.64%-241K	41.44%-65K	-2.26%-226K	-32.14%-111K	-9.41%-221K
Profit attributable to shareholders	2.17%-66.76M	-37.28%-25.79M	20.70%-68.24M	-551.91%-18.79M	-205.69%-86.06M	-89.83%4.16M	39.62%81.42M	16,792.56%40.88M	246.57%58.32M	-98.41%242K
Basic earnings per share	2.33%-0.126	-40.00%-0.049	20.37%-0.129	-537.50%-0.035	-205.19%-0.162	-89.61%0.008	40.00%0.154	0.077	243.75%0.11	0
Diluted earnings per share	2.33%-0.126	-40.00%-0.049	20.37%-0.129	-537.50%-0.035	-205.19%-0.162	-89.61%0.008	40.00%0.154	0.077	243.75%0.11	0
Currency Unit	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY
Accounting Standards	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS
Audit Opinions	--	--	--	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--
Auditor	PwC Zhongtian Certified Public Accountants (Special General Partnership)	--	PwC Zhongtian Certified Public Accountants (Special General Partnership)	--	PwC Zhongtian Certified Public Accountants (Special General Partnership)	--	PwC Zhongtian Certified Public Accountants (Special General Partnership)	--	PwC Zhongtian Certified Public Accountants (Special General Partnership)	--

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More

牛牛課堂

Oct 13, 2025 18:05

[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?

Food流油

Apr 14, 2025 15:43

"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"